Quaternary ammonium salts
Apexbio Technology LLC Choline Fenofibrate 100mg
A3308 is a small molecule designed for biomedical research applications though detailed structural and registry data are currently unavailable Its mechanism of action centers on modulating specific cellular pathways enabling the investigation of signaling events critical to various physiological and pathological processes A3308 s utility is primarily as a research tool to elucidate molecular targets and cellular responses supporting studies in signal transduction pathway characterization and potential therapeutic target identification
Apexbio Technology LLC Choline Fenofibrate 50mg
A3308 is a small molecule designed for biomedical research applications though detailed structural and registry data are currently unavailable Its mechanism of action centers on modulating specific cellular pathways enabling the investigation of signaling events critical to various physiological and pathological processes A3308 s utility is primarily as a research tool to elucidate molecular targets and cellular responses supporting studies in signal transduction pathway characterization and potential therapeutic target identification
Cambridge Isotope Laboratories Tetramethylammonium deuteroxide 5D2O (D13 98%) 1 g
Tetramethylammonium deuteroxide 5D2O (D13 98%) 1 g
Apexbio Technology LLC NS 1643 448895-37-2 10mg
NS 1643 (CAS 448895-37-2) is a small-molecule partial agonist of the human hERG potassium channel exhibiting an EC50 of 10 5 M In murine models of triple-negative breast cancer (TNBC) NS 1643 has been shown to inhibit tumor growth via specific signaling pathways Experimental studies demonstrate that NS 1643 suppresses both migration and invasion of breast cancer cells Due to these properties NS 1643 serves as a valuable tool for investigating hERG channel modulation and its impact on cancer cell behavior with potential applications in preclinical oncology research
Apexbio Technology LLC Tetraethylammonium chloride 56-34-8 50mg
Tetraethylammonium chloride (CAS 56-34-8) is a quaternary ammonium compound widely used as a potassium channel blocker in pharmacological and physiological studies It inhibits potassium channels by binding to internal and external sites at the channel pore thereby blocking ion conduction This property enables its use in investigations of potassium channel structure function and mutagenesis In vitro tetraethylammonium compounds have been essential for probing channel permeability and gating mechanisms In vivo studies indicate that TEA attenuates taurine-induced vasorelaxation in rat arteries Clinically its ganglionic blocking activity has been explored for circulatory disorders
Medchemexpress LLC Cholic acid sodium | 361-09-1 | 99.9% | 430.55 | 10 G
Cholic acid sodium is an endogenous metabolite and a major primary bile acid that is produced in the liver and typically conjugated with glycine or taurine. It plays a role in facilitating fat absorption and cholesterol excretion and is orally active. This product is intended for research use only.
- Major primary bile acid.
- Produced in the liver and typically conjugated with glycine or taurine.
- Facilitates fat absorption and cholesterol excretion.
- Orally active.
- Competitively binds Na+/taurocholate cotransporting polypeptide (NTCP) on HepG2 cells, inhibiting the uptake of CA-nanoliposomes-Doxorubicin-HCl.
- In vivo, it has been shown to decrease SHP protein expression and increase CYP2D6 expression and activity.
Medchemexpress LLC Cholic acid | 81-25-4 | 99.8% | 408.57 | 1 G
Cholic acid is a major primary bile acid produced in the liver, commonly conjugated with glycine or taurine. It plays a crucial role in facilitating fat absorption and cholesterol excretion, and is orally active.
- Major primary bile acid
- Produced in the liver
- Conjugated with glycine or taurine
- Facilitates fat absorption
- Aids cholesterol excretion
- Orally active
- Competitively binds Na+/taurocholate cotransporting polypeptide (NTCP)
- Decreases SHP protein expression
- Increases CYP2D6 expression and activity
![eMolecules 1112-67-0 | Tetrabutylammonium chloride | Combi-Blocks | MFCD00011635 | 277.920 | C16H36ClN | 95.000 | [Cl-].CCCC[N+](CCCC)(CCCC)CCCC | 100g | 117540901](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000216501.jpg-250.jpg)
eMolecules 1112-67-0 | Tetrabutylammonium chloride | Combi-Blocks | MFCD00011635 | 277.920 | C16H36ClN | 95.000 | [Cl-].CCCC[N+](CCCC)(CCCC)CCCC | 100g | 117540901
Tetrabutylammonium chloride | Combi-Blocks | 1112-67-0 | MFCD00011635 | 277.920 | C16H36ClN | 95.000 | [Cl-].CCCC[N+](CCCC)(CCCC)CCCC | 100g | 117540901
![eMolecules 461-05-2 | DL-carnitine hydrochloride | Combi-Blocks, Inc. | MFCD00011904 | 197.660 | C7H16ClNO3 | 97.000 | [Cl-].C[N+](C)(C)CC(O)CC(O)=O | 5g | 569288434](https://assets.fishersci.com/TFS-Assets/CCG/product-images/502183915.JPG-250.jpg)
eMolecules 461-05-2 | DL-carnitine hydrochloride | Combi-Blocks, Inc. | MFCD00011904 | 197.660 | C7H16ClNO3 | 97.000 | [Cl-].C[N+](C)(C)CC(O)CC(O)=O | 5g | 569288434
DL-carnitine hydrochloride | Combi-Blocks, Inc. | 461-05-2 | MFCD00011904 | 197.660 | C7H16ClNO3 | 97.000 | [Cl-].C[N+](C)(C)CC(O)CC(O)=O | 5g | 569288434
![eMolecules 22307-72-8 | Tetra-n-butylammonium salicylate | Combi-Blocks, Inc. | MFCD00145388 | 379.585 | C23H41NO3 | 97.000 | Oc1ccccc1C([O-])=O.CCCC[N+](CCCC)(CCCC)CCCC | 5g | 569297590](https://assets.fishersci.com/TFS-Assets/CCG/product-images/502187918.JPG-250.jpg)
eMolecules 22307-72-8 | Tetra-n-butylammonium salicylate | Combi-Blocks, Inc. | MFCD00145388 | 379.585 | C23H41NO3 | 97.000 | Oc1ccccc1C([O-])=O.CCCC[N+](CCCC)(CCCC)CCCC | 5g | 569297590
Tetra-n-butylammonium salicylate | Combi-Blocks, Inc. | 22307-72-8 | MFCD00145388 | 379.585 | C23H41NO3 | 97.000 | Oc1ccccc1C([O-])=O.CCCC[N+](CCCC)(CCCC)CCCC | 5g | 569297590